Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 80Neoplasms 14Neoplasm Metastasis 14Brain Neoplasms 9Breast Neoplasms, Male 7Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Stomach Neoplasms 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1

Interventions

Trastuzumab 2pyrotinib 1pertuzumab 1Vinorelbine 1Lapatinib 1Docetaxel 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2 Positive Breast Cancer × Lapatinib × Clear all
NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Completed
159 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡